Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?

References

• Trousseau A. Lectures on clinical medicine delivered at the Hotel-Dieu, Paris [translated by Cormack JR]. 5th ed. London: New Sydenham Society; 1872. p. 281–295.
   Google Scholar
• Dvorak HF, Rickles FR. Malignancy and hemostasis. In: VJ Marder, AW Clowes, JN George, et al. editor. Hemostasis and thrombosis, basic principles and clinical practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 851–873.
   Google Scholar
• Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hämostaseologie. 2012;32:115–125. doi: 10.5482/ha-1170
   PubMed Web of Science ®Google Scholar
• Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res. 2009;148:31–41. doi: 10.1007/978-0-387-79962-9_3
   PubMedGoogle Scholar
• Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97(8):1158–1164. doi: 10.3324/haematol.2011.054718
   PubMed Web of Science ®Google Scholar
• Mohren M, Jentsch-Ullrich K, Koenigsmann M, et al. High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia. Int J Hematol. 2016;103:189–195. doi: 10.1007/s12185-015-1913-y
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008;113:1605–1613. doi: 10.1002/cncr.23785
   PubMed Web of Science ®Google Scholar
• Tian T, Wang M, Ma D. TNF-α, a good or bad factor in hematological diseases? Stem Cell Investig. 2014;1:12.
   PubMedGoogle Scholar
• Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother. 2013;40:336–343. doi: 10.1159/000354194
   PubMed Web of Science ®Google Scholar
• Warzocha K, Bienvenu J, Ribeiro P, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin’s disease patients. Br J Cancer. 1998;77:2357–2362. doi: 10.1038/bjc.1998.391
   PubMed Web of Science ®Google Scholar
• Salles G, Bienvenu J, Bastion Y, et al. Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol. 1996;93:352–359. doi: 10.1046/j.1365-2141.1996.5181059.x
   PubMed Web of Science ®Google Scholar
• Warzocha K, Salles G, Bienvenu J, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol. 1997;15:499–508. doi: 10.1200/JCO.1997.15.2.499
   PubMed Web of Science ®Google Scholar
• Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res. 1996;56:5499–5505.
   PubMed Web of Science ®Google Scholar
• Jourdan M, Tarte K, Legouffe E, et al. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999;10:65–70.
   PubMed Web of Science ®Google Scholar
• Jurisić V, Colović M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2- microglobulin, and clinical stage in multiple myeloma. Med Oncol. 2002;19:133–139. doi: 10.1385/MO:19:3:133
   PubMed Web of Science ®Google Scholar
• Jöhrer K, Janke K, Krugmann J, et al. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine upregulation of MCP-1. Clin Cancer Res. 2004;10:1901–1910. doi: 10.1158/1078-0432.CCR-1053-03
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61:885–891. doi: 10.1016/j.cyto.2012.12.023
   PubMed Web of Science ®Google Scholar
• Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122:143–159. doi: 10.1042/CS20110340
   PubMed Web of Science ®Google Scholar
• Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110:1911–1928. doi: 10.1002/cncr.22999
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Lu ZY, et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863–872.
   PubMed Web of Science ®Google Scholar
• Burger R, Wendler J, Antoni K, et al. Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop. Ann Hematol. 1994;69:25–31. doi: 10.1007/BF01757344
   PubMed Web of Science ®Google Scholar
• Hoppe B. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation. Thromb Haemost. 2014;112:649–658. doi: 10.1160/TH14-01-0085
   PubMed Web of Science ®Google Scholar
• Berger MD, Heini AD, Seipel K, et al. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. Hematol Oncol. 2016. doi: 10.1002/hon.2307
   Web of Science ®Google Scholar
• Hensen A, Loeliger EA. Antithrombin III. Its metabolism and its function in blood coagulation. Thromb Diath Haemorrh. 1963;83(Suppl 1):1–84.
   Google Scholar
• Dixit A, Kannan M, Mahapatra M, et al. Roles of protein C, protein S, and antithrombin III in acute leukemia. Am J Hematol. 2006;81:171–174. doi: 10.1002/ajh.20546
   PubMed Web of Science ®Google Scholar
• Sun W, Ren H, Gao C, et al. Clinical and prognostic significance of coagulation assays in pancreatic cancer patients with absence of venous thromboembolism. Am J Clin Oncol. 2015;38(6):550–556. doi: 10.1097/01.coc.0000436088.69084.22
   PubMed Web of Science ®Google Scholar
• Iwako H, Tashiro H, Amano H, et al. Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 2012;19:2888–2896. doi: 10.1245/s10434-012-2338-y
   PubMed Web of Science ®Google Scholar
• Kuusisto ML, Haapasaari KM, Remes AM, et al. Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma. Ann Hematol. 2015;94:1167–1174. doi: 10.1007/s00277-015-2334-y
   PubMed Web of Science ®Google Scholar
• Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets. 2007;8(9):962–970. doi: 10.2174/138945007781662364
   PubMed Web of Science ®Google Scholar
• Stefansson S, McMahon GA, Petitclerc E, et al. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des. 2003;9(19):1545–1564. doi: 10.2174/1381612033454621
   PubMed Web of Science ®Google Scholar
• Wada H, Kumeda Y, Ogasawara Z, et al. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol. 1993;42:166–170. doi: 10.1002/ajh.2830420205
   PubMed Web of Science ®Google Scholar
• Wang WS, Lin JK, Lin TC, et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol. 2005;11:2166–2170. doi: 10.3748/wjg.v11.i14.2166
   PubMed Web of Science ®Google Scholar
• Yang X, Sun H, Li Z, et al. Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer. 2015;15:49. doi: 10.1186/s12885-015-1042-2
   PubMed Web of Science ®Google Scholar
• Röhsig LM, Damin DC, Stefani SD, et al. von Willebrand factor antigen levels in plasma of patients with malignant breast disease. Braz J Med Biol Res. 2001;34(9):1125–1129. doi: 10.1590/S0100-879X2001000900004
   PubMed Web of Science ®Google Scholar
• Minnema MC, Fijnheer R, De Groot PG, et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haem. 2003;1:445–449. doi: 10.1046/j.1538-7836.2003.00083.x
   PubMed Web of Science ®Google Scholar
• Hivert B, Caron C, Petit S, et al. Clinical and prognostic implications of low or high level von Willebrand factor in patients with Waldenström macroglobulinemia. Blood. 2012;120:3214–3221. doi: 10.1182/blood-2011-11-388256
   PubMed Web of Science ®Google Scholar
• Kastritis E, Papassotiriou I, Terpos E, et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood. 2016;128(3):405–409. doi: 10.1182/blood-2016-02-702696
   PubMed Web of Science ®Google Scholar
• Ay C, Jungbauer LV, Sailer T, et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem. 2007;53:1235–1243. doi: 10.1373/clinchem.2006.085068
   PubMed Web of Science ®Google Scholar
• Muz B, Azab F, de la Puente P, et al. Inhibition of P-selectin and PSGL-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib. Biomed Res Int. 2015;2015:417–586. doi: 10.1155/2015/417586
   Web of Science ®Google Scholar
• Aref S, Salama O, Al-Tonbary Y, et al. L and E selectins in acute myeloid leukemia: expression, clinical relevance and relation to patient outcome. Hematology. 2002;7(2):83–87. doi: 10.1080/10245330290028579
   PubMedGoogle Scholar
• Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis. 1998;32:S118–S125. doi: 10.1016/S0272-6386(98)70174-X
   PubMed Web of Science ®Google Scholar
• Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer. 1999;35:106–110. doi: 10.1207/S15327914NC352_2
   PubMed Web of Science ®Google Scholar
• Kim JE, Yoo C, Lee DH, et al. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 2010;89:391–397. doi: 10.1007/s00277-009-0841-4
   PubMed Web of Science ®Google Scholar